Dabrafenib (BRAF inhibitor) and Selumetinib (MEK inhibitor) have already demonstrated both tolerability and clinical activity in paediatric patients with solid tumours such as gliomas, neuroblastomas and thyroid cancers during phase I and II trials [11–13]. Here, BRAF is linked to thyroid cancer.